05/08/2020

Cell Lab | Anapharm Bioanalytics expands its laboratory capabilities

We are glad to inform you that a cell lab has recently been built at our facilities in Barcelona. Such expansion of our services’ portfolio is in response to client’s growing demand for cell-based assays and is aligned with Anapharm’s grow strategy towards providing effective solutions for its clients worldwide.

Our brand new cell lab capabilities will enable the development and validation of a variety of assays such as Cell Proliferation, Ligand Stimulated Cell Signalling, Protein Secretion, Reporter Gene, NAbs, etc. The results’ readouts include Absorbance, Fluorescence and Luminescence.

”This is an important addition to our offering and a step forward towards providing better assistance to our clients’ drug Development programs” said Dr. Salvatore Scarpaci, Large Molecule Bioanalysis Director at Anapharm Bioanalytics.

We strive to exceed Sponsor’s expectations by delivering great value services and we look forward to supporting our clients’ evolving needs time after time.

If you are interested in having additional details please let us know.

About Anapharm Bioanalytics

15+ years’ experience in LBA assays for antibodies and biomarkers and 30+ years’ experience in LC/MS-MS bioanalysis, acknowledges Anapharm Bioanalytics as a world class provider of bioanalytical services to international Sponsors with its strategically located, GLP-certified and GCP-compliant laboratory in Barcelona.

With a successful regulatory history, having undergone 20 successful inspections from health agencies, including FDA (14 studies), GCP inspections from Austria, Italy and Spain (10+ studies), as well as GLP certifications by EU authorities and ANVISA (Brazil), Anapharm has become a reliable analytical partner to support its clients at any stage of drug development from preclinical throughout all clinical stages Phase I-IV.

For further details about Anapharm Bioanalytics, please visit https://www.anapharmbioanalytics.com/services/ or contact your Business Development representative at +34 93 223 8636.

MORE NEWS

02/12/2021 14:33

Challenges in the Detection of Metabolic Biomarkers Using a Multi Plex Assay

A 5 Plex method for the detection of metabolic biomarkers in human plasma was developed using the U-PLEX technology on the MSD platform.

The complexities surrounding this method were the establishment of endogenous QCs for each chosen biomarker and evaluating the potential use and need for buffer QCs vs matrix QCs where applicable. Additional challenges were faced while trying to ascertain a single minimum required dilution to enable accurate quantification of all biomarkers simultaneously, encompassing the different detection ranges and limits for each biomarker.

READ MORE
02/12/2021 10:27

Considerations to properly assess drug stability within biological samples

Assessing drug stability during method development and validation is of paramount importance. The concentration of the target analyte must remain unaffected throughout the lifecycle of the samples to ensure the reliability of the assay data. However, a decrease in analyte concentration in a biological fluid is not always due to a lack of stability.

READ MORE
14/06/2021 15:46

Challenges in development of robust analytical methods for the quantitation of low molecular weight compounds by LC-MS/MS

Method development can be considered one of the most challenging task in a Bioanalytical laboratory. When working with LC-MS/MS and low molecular weight drugs, low degree of ionization, poor fragmentation, higher presence of isobaric compounds or analyte loss due to their high volatility can get in the way of a successful method development.

READ MORE